PDB56 COSTS ASSOCIATED WITH INITIATING EMPAGLIFLOZIN VERSUS OTHER ANTIHYPERGLYCEMIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE: A RETROSPECTIVE COHORT STUDY
Abstract
Authors
P. Pimple A. Raju D. Stafkey-Mailey S. Shetty